Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
Background There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial growth factor antibody bevacizumab remains the mainstay of advanced treatment. Pembrolizumab is Food and Drug Agency approved for p...
        Saved in:
      
    
          | Main Authors: | Dmitriy Zamarin, Siqing Fu, Elad Sharon, Travis J Hollmann, Alexia Iasonos, Jason A Konner, Susan C Modesitt, Qin Zhou, Alexandre Buckley De Meritens, Carol Aghajanian, Claire F Friedman, Panagiotis A Konstantinopoulos, Bradley R Corr, Michael A Carducci, Alexandra Snyder Charen | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | BMJ Publishing Group
    
        2020-10-01 | 
| Series: | Journal for ImmunoTherapy of Cancer | 
| Online Access: | https://jitc.bmj.com/content/8/2/e001126.full | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination        
                          
 by: Takahiro Niimura, et al.
 Published: (2023-08-01)
- 
                
                    Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma        
                          
 by: Parissa Tabrizian, et al.
 Published: (2025-02-01)
- 
                
                    Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”        
                          
 by: Naoshi Nishida
 Published: (2024-10-01)
- 
                
                    Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab        
                          
 by: Meng Wu, et al.
 Published: (2025-02-01)
- 
                
                    Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy        
                          
 by: Hironori Ochi, et al.
 Published: (2025-01-01)
 
       